Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 12—December 2024
Research

Clinical Manifestations, Antifungal Drug Susceptibility, and Treatment Outcomes for Emerging Zoonotic Cutaneous Sporotrichosis, Thailand

Pattriya Jirawattanadon, Sumanas Bunyaratavej, Charussri Leeyaphan, Piriyaporn Chongtrakool, Panitta Sitthinamsuwan, Waratchaya Panjapakkul, Suthasanee Prasertsook, Phuwakorn Saengthong-aram, Nicha Wareesawetsuwan, Julaluck Posri, and Penvadee PattanaprichakulComments to Author 
Author affiliation: Siriraj Hospital Faculty of Medicine, Bangkok, Thailand

Main Article

Figure 1

Numbers of sporotrichosis cases during 2018–2022 in study of clinical manifestations, antifungal drug susceptibility, and treatment outcomes for emerging zoonotic cutaneous sporotrichosis, Thailand. Line indicates the total number of cases each year. Numbers above each bar indicate the number of patients exposed or not exposed to cats.

Figure 1. Numbers of sporotrichosis cases during 2018–2022 in study of clinical manifestations, antifungal drug susceptibility, and treatment outcomes for emerging zoonotic cutaneous sporotrichosis, Thailand. Line indicates the total number of cases each year. Numbers above each bar indicate the number of patients exposed or not exposed to cats.

Main Article

Page created: September 24, 2024
Page updated: November 26, 2024
Page reviewed: November 26, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external